NASDAQ:EQRX EQRx (EQRX) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free EQRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.34▼$2.3450-Day Range$2.04▼$2.4752-Week Range$1.58▼$5.55VolumeN/AAverage Volume3.30 million shsMarket Capitalization$1.14 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get EQRx alerts: Email Address Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About EQRx Stock (NASDAQ:EQRX)EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. As of November 9, 2023, EQRx, Inc. operates as a subsidiary of Revolution Medicines, Inc.Read More Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. EQRX Stock News HeadlinesMay 7, 2024 | finance.yahoo.com599 Cancer Monoclonal Antibody Collaboration and Licensing Deals Report and Directory 2016-2024February 28, 2024 | finance.yahoo.comRevolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call TranscriptMay 11, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. February 27, 2024 | finanznachrichten.deRevolution Medicines, Inc.: Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate ProgressFebruary 26, 2024 | uk.finance.yahoo.comRevolution Medicines Inc (RVMD) Reports Earnings: R&D Investments Surge Amidst Clinical ProgressFebruary 21, 2024 | msn.comAbCellera Biologics (ABCL) Q4 2023 Earnings Call TranscriptFebruary 1, 2024 | morningstar.comGubra AS GUBRANovember 14, 2023 | msn.comSoftBank adds stakes in Neumora, Globalstar in Q3; stake in WeWork slashedMay 11, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. November 9, 2023 | finanznachrichten.deRevolution Medicines, Inc.: Revolution Medicines and EQRx Stockholders Approve EQRx AcquisitionNovember 9, 2023 | finanznachrichten.deRevolution Medicines, Inc.: Revolution Medicines Completes Acquisition of EQRxNovember 8, 2023 | msn.comRevolution Medicines and EQRx stockholders approves acquisitionNovember 7, 2023 | finanznachrichten.deRevolution Medicines, Inc.: Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate ProgressNovember 2, 2023 | finance.yahoo.comWe're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash WiselyOctober 20, 2023 | barrons.comCalling All EQRx, Inc. (EQRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your LossesOctober 8, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, NEWR, EQRX, SCUSeptember 27, 2023 | benzinga.comEQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of ShareholdersSeptember 26, 2023 | finance.yahoo.comApplied BioMath, LLC Hosts 6th Annual Quantitative Systems Pharmacology SummitAugust 3, 2023 | businesswire.comEQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRXAugust 1, 2023 | msn.comRevolution Medicines will buy EQRx in an all-stock transactionAugust 1, 2023 | bizjournals.comEQRx sells to another Alexis Borisy biotech after multiple pivotsAugust 1, 2023 | finance.yahoo.comRevolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional CapitalAugust 1, 2023 | businesswire.comEQRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of EQRx, Inc. Is Fair to ShareholdersJune 29, 2023 | finance.yahoo.comEQRx, Inc. (NASDAQ:EQRX) has caught the attention of institutional investors who hold a sizeable 47% stakeMay 19, 2023 | seekingalpha.comCStone Breaks Up With Drugs Partner As U.S. Rollout StallsMay 10, 2023 | msn.comThe World Has Its Way With EQRxMay 9, 2023 | finance.yahoo.comQ1 2023 EQRx Inc Earnings CallSee More Headlines Receive EQRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EQRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:EQRX CUSIPN/A CIK1843762 Webiii.cmlifesciencesspac.com Phone617-315-2255FaxN/AEmployees362Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-169,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.33% Return on Assets-19.32% Debt Debt-to-Equity RatioN/A Current Ratio18.77 Quick Ratio22.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.40 per share Price / Book0.98Miscellaneous Outstanding Shares487,420,000Free Float398,218,000Market Cap$1.14 billion OptionableOptionable Beta0.48 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Alexis A. Borisy A.M. (Age 51)Founder & Executive Chairman of Board of Directors Ms. Melanie I. Nallicheri (Age 54)President, CEO, Principal Executive & Financial Officer and Director Comp: $931.75kMs. Dina Ciarimboli J.D. (Age 54)General Counsel & Corporate Secretary Comp: $628.63kMr. Robert Forrester LL.B. (Age 59)Co-Founder & Advisor Dr. Peter B. Bach M.D. (Age 58)MAPP, Co-Founder & Advisor Sir Andrew Dillon CBECo-Founder & AdvisorMr. Daniel Hoey (Age 56)Chief of Technical Operations Ms. Rona Anhalt (Age 58)Chief People Officer Dr. Carlos Garcia-Echeverria Ph.D. (Age 58)Chief of RX Creation Dr. Eric E. Hedrick M.D. (Age 58)Chief Physician Executive Comp: $575.1kMore ExecutivesKey CompetitorsEnliven TherapeuticsNASDAQ:ELVNScholar RockNASDAQ:SRRKAbCellera BiologicsNASDAQ:ABCLVerona PharmaNASDAQ:VRNABioCryst PharmaceuticalsNASDAQ:BCRXView All Competitors This page (NASDAQ:EQRX) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeCollapse of the Petrodollar Colonial MetalsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EQRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.